INSIGHTS ON LIQUID DOSE MANUFACTURING
-
Generate CHO-K1 GFP-Expressing Cells For Cell Line Development Workflow
Discover a high-efficiency workflow for generating GFP-expressing CHO-K1 clones using automated single-cell dispensing to achieve 93% isolation success and stable expression in under five weeks.
-
Aseptic Filling Solution Enhances Sterility Assurance for Pharma Manufacturer
Emergent BioSolutions upgraded its Winnipeg site with the Cytiva SA25 aseptic filling workcell to improve sterility assurance, product flexibility, and regulatory compliance for CGT manufacturing.
-
Product-Wet Integrity Testing: Risk-Based Strategies
When standard water‑based integrity testing falls short, product‑wet approaches can offer a more representative alternative. Learn how risk‑based strategies are used to establish reliable test limits.
-
A Standardized Gloveless Robotic Isolator
By eliminating human intervention—the primary risk factor compromising drug sterility and quality—gloveless aseptic processing technology offers manufacturers greater flexibility, safety, and regulatory compliance in their filling operations.
-
Delivering Simplicity Without Compromise7/2/2026
Optimize biopharma drug delivery with a flexible platform adapting to multiple syringe formats. Streamline manufacturing, secure dual-source supply, and encourage patient independence.
-
De-Risking A Novel Valve Component For Use With Standard Syringe Systems3/16/2026
A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.
-
Advancing TIDES Manufacturing Through Biocatalysis And Flow Technologies4/17/2026
Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.
-
Unlock Large-Volume Drug Delivery With Vertiva® On-Body Delivery System7/2/2026
See a large-volume drug delivery with a pre-filled, pre-loaded on-body device. Its programmable dosing profiles and reusable controller offer sustainable treatment while minimizing patient use errors.
-
Finding The Right Aseptic Processing Approach8/28/2024
How should you approach building your aseptic processing line? Gain insight into the advantages of using a modular, configurable technology rather than custom fill-finish solutions.
LIQUID DOSE MANUFACTURING SOLUTIONS
-
Advance your cell processing capabilities with high-containment isolation. Ensure cGMP compliance and superior sterile protection for your most sensitive and critical biological workflows.
-
ASEPTiCell is integrated with isolator-barrier technologies to fully enclose and tightly control the aseptic environment for ideal conditions for processing sterile drug products. The system can be configured with a Restricted Access Barrier System (RABS) or an aseptic isolator to provide uninterrupted aseptic conditions during production. With isolator integrated systems, the ASEPTiCell is completely compatible with repeated in-situ bio-decontamination using hydrogen peroxide to further enhance the sterility assurance of the system.
-
DCS® Liquid was specifically developed for toxic and corrosive liquids, achieving containment levels of < 1 ppb. The safe and contained emptying and filling of drums is thus made possible without additional precautions, such as full protective clothing or large laminar airflow booths.
-
Oral solid dose manufacturing supports complex formulations with flexible scales, specialized technologies, and integrated packaging for reliable clinical and commercial supply.
-
Cell and gene therapies have increased in popularity in recent years, and thanks to their ability to provide one-time treatments these therapies will play a significant role in treating some of the world's most challenging diseases. These drug products treat patients afflicted with genetic disorders and cancers by targeting the source of disease and altering its genetic makeup to eliminate its cause or symptoms. These therapies are expensive and complex and have been proven effective in numerous cases, but they present a challenge in producing them at scale and at a reasonable cost.